RNA therapy has broad applicability for genetic diseases. After we focused on inherited retinal diseases we spun out non-core activities in several independent biotech companies.
In 2019 we spun out the dystrophic epidermolysis bullosa (DEB) activities into the newly formed company, Wings Therapeutics. Wings Therapeutics was formed and financed by EB Research Partnership (EBRP), the largest global non-profit dedicated to treating and curing EB.
In 2017 we spun out the central nervous system activities into the newly formed company, Amylon Therapeutics. As part of the transaction, ProQR granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders.